BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis
A live, multi-source view of BioCryst Pharmaceuticals, Inc. (BCRX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · United States · 435 employees · biocryst.com
Key statistics · as of 2026-09-05
As of 2026-09-05, BioCryst Pharmaceuticals, Inc. (BCRX) had a market capitalization of $2.55B (forward 10.6) and a beta of 0.56; the shares traded in a 52-week range of $6.00 – $11.22 (23.2% over the year).
- Market cap
- $2.55B
- Enterprise value
- $3.03B
- Forward P/E
- 10.6
- PEG ratio
- 9.39
- EPS (trailing)
- $-1.38
- EPS (forward)
- $0.94
- Payout ratio
- 0.0%
- 52-week range
- $6.00 – $11.22
- 52-week change
- 23.2%
- Beta
- 0.56
- Average volume
- 4.3M
- Shares outstanding
- 255.5M
- Short % of float
- 12.99%
- Profit margin
- -40.9%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, BioCryst Pharmaceuticals, Inc. (BCRX) last closed at $9.96 (the last completed close before that scan).
Technicals at the scan: RSI 54 (neutral territory), price +0.5% versus its 20-day average, 20-day versus 50-day average spread +1.6%, MACD histogram 0.02.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; analyst consensus score 80/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 1 buy and 0 sells of BCRX; corporate insiders filed 0 buys and 0 sells (1 filer, latest disclosure 2026-09-04). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Gilbert Ray Cisneros, Jr. (1B/0S). Who is trading what
RapidTradeView pick record
BCRX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls BioCryst Pharmaceuticals, Inc. (BCRX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell BCRX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.